The rise of antimicrobial resistance: A clear and present danger

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 6, 2011, Pages 645-648

  Holmes, Natasha E ^a   Howden, Benjamin P ^a,b,c  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; BETA LACTAMASE; CARBAPENEM; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; PSEUDOMONIC ACID; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; COMMUNICABLE DISEASE; DISEASE TRANSMISSION; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HEALTH CARE; HUMAN; INFECTION CONTROL; MEDICAL EXPERT; MEDICAL SOCIETY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; PLASMID; SCCMEC II GENE; SCCMEC III GENE; SHIGELLA BOYDII; SINGLE NUCLEOTIDE POLYMORPHISM; VIBRIO CHOLERAE;

ANTI-BACTERIAL AGENTS; ASIA; AUSTRALIA; CONGRESSES AS TOPIC; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EUROPE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; NEW ZEALAND; NORTH AMERICA; SPAIN; STAPHYLOCOCCAL INFECTIONS; UNITED STATES;

EID: 79959755207     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.49     Document Type: Article

References (23)

1. Tenover FC, McAllister S, Fosheim G et al. Characterization of Staphylococus aureus isolates from nasal cultures collected from individuals in the United States in 2001 to 2004. J. Clin. Microbiol., 46 2837-2841 (2008).
2. D'Agata EMC, Webb GF, Horn MA, Moellering RC Jr., Ruan S. Modeling the invasion of community-acquired methicillin-resistant Staphylococcus aureus into hospitals. Clin. Infect. Dis. 48, 274-284 (2009).
3. Li M, Diep BA, Villaruz AE et al. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc. Natl Acad. Sci. USA 106,5883-5888 (2009).
4. Kennedy AD, Otto M, Braughton KR et al. Epidemic community-associated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversification. Proc. Natl Acad. Sci. USA 105, 1327-1332 (2008).
5. Centers for Disease Control and Prevention (CDC). Methicillin-resistant Staphylococcus aureus skin infections from an elephant calf - San Diego, California, 2008. MMWR Morb. Mortal. Wkly Rep. 58, 194-198 (2009).
6. Soge OO, Meschke JS, No DB, Roberts MC. Characterization of methicllin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative Staphylococcus spp. isolated from US West Coast public marine beaches. J. Antimicrob. Chemother. 64, 1148-1155 (2009).
7. McDougal LK, Fosheim GE, Nicholson A et al. Emergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolates causing invasive disease in the United States. Antimicrob. Agents Chemother. 54, 3804-3811 (2010).
8. Graber CJ, Wong MK, Carleton HA, Perdreau-Remington F, Haller BL, Chambers HF. Intermediate vancomycin susceptibility in a community-associated MRSA clone. Emerg. Infect. Dis. 13, 491-493 (2007).
9. Hagema JC, Patel J, Franklin P et al. Occurrence of a USA300 vancomycin-intermediate Staphylococcus aureus Diagn. Microbiol. Infect. Dis. 62, 440-442 (2008).
10. Shore A, Brennan OM, Ehricht R et al. Identification and characterization of the multidrug resistance gene cfr in a Panton-Valentine leukocidin-positive sequence type 8 methicillin-resistant Staphylococcus aureus IVa (USA300) isolate. Antimicrob. Agents Chemother. 54, 4978-4984 (2010).
11. Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10, 597-602 (2010).
12. Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN, Mendes RE. Early dissemination of NDM-1 and OXA-181-producing Enterobacteriaceae in Indian hospitals: Report from the SENTRY Antimicrobial Surveillance Program, 2006-2007. Antimicrob. Agents Chemother. 55,1274-1278 (2011).
13. Tato M, Morosini M, Garcia L, Alberti S, Coque MT, Canton R. Carbapenem heteroresistance in VIM-1-producing Klebsiella pneumoniae isolates belonging to the same clone: consequences for routine susceptibility testing. J. Clin. Microbiol. 48, 4089-4093 (2010).
14. Souli M, Konstandtinidou E, Tzepi I et al. Efficacy of carbapenems against a metallo-β-lactamase-producing Escherichia coli clinical isolate in a rabbit intra-abdominal abscess model. J. Antimicrob. Chemother. 66, 611-617 (2011).
15. Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J. Antimicrob. Chemother. 61, 636-642 (2008).
16. Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin. Microbiol. Infect. 16, 184-186 (2010).
17. Urban C, Mariano N, Rahal JJ. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob. Agents Chemother. 54, 2732-2734 (2010).
18. Canton R. Antibiotic resistance genes from the environment: a perspective through newly identified antibiotic resistance mechanisms in the clinical setting. Clin. Microbiol. Infect. 15 (Suppl. 1), 20-25 (2009).
19. D'Costa VM, McGrann KM, Hughes DW, Wright GD. Sampling the antibiotic resistome. Science 311, 374-377 (2006).
20. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect. Dis. 11(5),355-362 (2011).
21. Laupland KB, Church DL, Vidakovich J, Mucenski M, Pitout JD. Community-onset extended-spectrum β -lactamase (ESBL) producing Escherichia coli: importance of international travel. J. Infect. 57, 441-448 (2008).
22. Tangden T, Cars O, Melhus A, Lowdin E. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum β -lactamases: a prospective study with Swedish volunteers. Antimicrob. Agents Chemother. 54,3564-3568 (2010).
23. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1-12 (2009).